UFP Technologies (UFPT) 47th Annual Raymond James Institutional Investor Conference summary
Event summary combining transcript, slides, and related documents.
47th Annual Raymond James Institutional Investor Conference summary
3 Mar, 2026Business overview and strategy
Focuses on contract development and manufacturing of single-use and single-patient medical devices, with $600M revenue, 5,000+ employees, and 21 manufacturing sites globally.
Differentiates through exclusive or semi-exclusive access to advanced materials, strong vendor partnerships, and in-house engineering and prototyping.
Product development is a high-margin, recurring revenue stream, feeding manufacturing and deepening expertise.
Major business segments: 55% devices, 17% sterile packaging, 28-29% robotic surgery, with fastest growth in largest markets.
Growth strategy is two-pronged: internal growth by targeting high-value segments and strategic acquisitions aligned with customer needs and technology roadmaps.
Operational highlights and market positioning
Holds exclusive access to key materials, serving 26 of the top 30 med device companies, and builds custom equipment to increase product stickiness.
Acquisitions have expanded capabilities and geographic reach, especially in low-cost countries and strategic markets like Ireland and the Dominican Republic.
Integration approach emphasizes cultural fit and growth synergies, often acquiring companies with strong customer concentration.
Recent acquisitions (e.g., DAS Medical, AJR) have rapidly scaled revenues and unlocked new business from existing customers.
Plans to expand into APAC within 12-18 months, co-investing with a major customer.
Financial performance and targets
Revenue has tripled and medical sales quadrupled in four years, with bottom-line growth of 400%.
Financial targets: 12-18% revenue growth (half internal, half acquisition), 28-31% gross margins, 17-20% adjusted operating margins.
One-time labor issue impacted margins but remains within target range; underlying growth trends remain strong.
Contract extensions with major customers have increased minimums and volumes, supporting further investment in capacity.
Latest events from UFP Technologies
- MedTech-focused manufacturer targets 12–18% revenue growth and 17–20% margins via innovation and acquisitions.UFPT
Investor presentation3 Mar 2026 - 2025 sales up 19.5% to $602.8M, with record net income and strong medical market growth.UFPT
Q4 202525 Feb 2026 - Exclusive materials, strategic acquisitions, and medtech focus drive robust growth and margins.UFPT
15th Annual Midwest IDEAS Investor Conference23 Jan 2026 - Executing on acquisitions and expanding in med tech, with strong customer partnerships and margin gains.UFPT
CJS Securities Annual New Ideas For the New Year Conference 202410 Jan 2026 - Exclusive materials, custom processes, and acquisitions fuel rapid Medtech growth and resilience.UFPT
Piper Sandler 37th Annual Healthcare Conference3 Dec 2025 - Annual meeting to vote on directors, executive pay, auditor, and governance practices.UFPT
Proxy Filing2 Dec 2025 - Record Q1 sales up 41% to $148.1M, led by medical growth and strategic expansion.UFPT
Q1 202524 Nov 2025 - Strong growth in medical device outsourcing, driven by innovation, acquisitions, and client focus.UFPT
16th Annual Midwest Ideas Conference23 Nov 2025 - Q2 sales up 37% to $151.2M, MedTech up 46%, with margin rebound expected in Q4.UFPT
Q2 202523 Nov 2025